BOTHELL, Wash., March 9, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced CEO Mike Rice will be presenting at two upcoming investor events;
- 28th Annual ROTH Conference; March 13-16, 2016 at the Ritz Carlton in Dana Point, CA. Presentation time: Tuesday, March 15th at 5:00PM. For more information please visit http://www.roth.com/main/page.aspx?PageID=7271
- 4th Annual Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day; Tuesday, March 22, 2016 at the Metropolitan Club in New York City. Presentation time: 4:05PM. Session moderated by Edward Tenthoff, Managing Director & Senior Research Analyst, Piper Jaffray. For more information please visit: http://arminvestorday.com/agenda/
Mike Rice, BioLife's President & CEO, said, "The ROTH conference and the ARM Cell & Gene Therapy Investor Day are key events, with agenda themes focused on our strategic markets and including presentations by numerous BioLife customers. I look forward to presenting on BioLife's growth opportunities and to meeting with investors at both conferences."
About the ROTH Conference:
ROTH Capital Partners invites you to join us for our 28th Annual Conference. This conference is one of the largest of its kind in the U.S. Following the success of previous years' events, the ROTH Conference, with over 500 participating companies and over 3,000 attendees, will feature presentations from hundreds of public and private companies.
About the ARM Cell & Gene Investor Day:
This one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.
About BioLife Solutions:
Our proprietary HypoThermosol® and CryoStor® biopreservation media products are critical enabling reagents used in the biobanking, drug discovery, and regenerative medicine markets. Our products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. These products provide commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. Our related biologistex cloud hosted biologistics cold chain management app for smart shippers offers enhanced track, trace, and notification services for shipments of time and temperature sensitive biologic materials. We also perform contract aseptic media formulation, fill, and finish services. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This press release contains forward-looking statements, including, but not limited to, statements concerning potential growth, business opportunities and the potential utility of and market for its products and services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding the performance of customers' clinical trials; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Media & Investor Relations Roderick de Greef Interim Chief Financial Officer (425) 402-1400 rdegreef@BioLifeSolutions.com
SOURCE BioLife Solutions, Inc.